Anzeige
Mehr »
Login
Montag, 04.03.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Diese Vervielfacher-Perlen gilt es jetzt im Depot zu haben…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
04.03.24
20:12 Uhr
146,30 Euro
-3,30
-2,21 %
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
146,30146,4020:12
146,30146,5020:13

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18:10With Takeda out of the picture, J&J's Rybrevant moves into first line in lung cancer subtype6
17:10J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer8
13:54Johnson & Johnson's Rybrevant granted FDA approval for lung cancer indications20
10:46FDA approves J&J's RYBREVANT for NSCLC treatment5
FrJohnson & Johnson's Rybrevant Gets FDA Approval For Lung Cancer Treatment550NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Friday announced that the U.S. Food and Drug Administration (FDA) has approved its drug Rybrevant in combination with chemotherapy as a first-line...
► Artikel lesen
FrJ&J gets full approval for Rebrevant for EGFR exon 20 lung cancer4
FrJohnson & Johnson: RYBREVANT (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations222Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone...
► Artikel lesen
FrFDA approves J&J's combination therapy for a type of lung cancer3
FrFDA approves JNJ's combination therapy for patients with a type of lung cancer3
FrFast Five: Medtronic asks ITC to stop Axonics' neuromod device sales; J&J's Varipulse PFA wins CE mark approval4
DoWith J&J settlement, Biocon Biologics gets a license to challenge Stelara in the US5
DoJ&J secures European afib approval for Varipulse pulsed field ablation system4
DoJ&J's Biosense Webster's Varipulse PFA system wins CE mark3
DoPharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK9
DoJohnson & Johnson Biosense Webster: Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform466Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow.Integrated with the world's leading CARTO 3D Cardiac Mapping System for...
► Artikel lesen
MiFast Five: A high-ranking BD executive is set to retire; J&J's Biosense Webster begins trial for Laminar LAA8
MiJohnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst12
DiJ&J's Biosense Webster begins trial for Laminar left atrial appendage elimination device6
DiJanssen's Carvykti recommended by CHMP for earlier multiple myeloma treatment3
DiShould You Pick Johnson & Johnson Stock At $160?13
Seite:  Weiter >>
727 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
5,1,45